FDA’s TEMPO pilot signals shift towards real-world evidence for digital health devices

The US FDA has selected Dexcom for its pioneering TEMPO programme, enabling digital health products to reach patients while gathering real-world performance data, marking a significant change in regulatory approach. The US Food and Drug Administration has picked Dexcom as…













